George Davis, MD
Psychiatry · Gautier, MSNPI 1700041308
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 26.6% of the total. Reporting peaked in 2023 at $1,280 and has fallen 61.9% since, to $487 in 2024.
Across 187 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$911
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$779
- Otsuka America Pharmaceutical, Inc.$236
- Vanda Pharmaceuticals Inc.$210
- Lundbeck LLC$203
- Neurocrine Biosciences, Inc.$202
- plus $889 from 11 others
What the payments were for
- Food & beverage$3,429100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $911 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $779 |
| Otsuka America Pharmaceutical, Inc. | 12 | $236 |
| Vanda Pharmaceuticals Inc. | 8 | $210 |
| Lundbeck LLC | 11 | $203 |
| Neurocrine Biosciences, Inc. | 10 | $202 |
| Teva Pharmaceuticals USA, Inc. | 11 | $194 |
| Johnson & Johnson | 9 | $160 |
| Sunovion Pharmaceuticals Inc. | 10 | $112 |
| Indivior Inc. | 4 | $91 |
| Alkermes, Inc. | 5 | $89 |
| Avanir Pharmaceuticals, Inc. | 5 | $73 |
| Corium, LLC | 3 | $60 |
| Almatica Pharma LLC | 3 | $56 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$487
How this compares
$3,429 in reported general payments places this provider in the 80th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 51 | $119,678 |
| RexultiBrexpiprazole | 38 | $89,533 |
| CaplytaLumateperone Tosylate | 25 | $40,660 |
| AristadaAripiprazole Lauroxil | 12 | $31,092 |
| VraylarCariprazine Hcl | 20 | $28,268 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $19,461 |
| Risperdal ConstaRisperidone Microspheres | 14 | $17,826 |
| TrintellixVortioxetine Hydrobromide | 21 | $10,012 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $9,339 |
| Fluphenazine Hcl | 32 | $5,569 |
| Clozapine | 40 | $3,811 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 54 | $2,836 |
| Quetiapine Fumarate | 108 | $2,703 |
| Divalproex Sodium ErDivalproex Sodium | 70 | $2,654 |
| Olanzapine | 129 | $2,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $160 | $137,50365 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $236 | $89,53338 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $779 | $40,66025 claims |
| Alkermes, Inc.Aristada | $89 | $31,09212 claims |
| AbbVieVraylar | $911 | $28,26820 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $73 | $19,46112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $18 | $19,35036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Gautier
- Maxie GordonClinton$1.3M
- Kurt BuechlerRidgeland$1.1M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
- Amy MillerSaltillo$82K
- Clyde GlennRidgeland$68K
- Krishan GuptaJackson$26K
- Joseph KwentusFlowood$13K
- Mark WebbRidgeland$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.